Head & Neck Squamous Cell Carcinoma Clinical Trials

6 recruiting

Head & Neck Squamous Cell Carcinoma Trials at a Glance

6 actively recruiting trials for head & neck squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Brest, Copenhagen, and Rome. Lead sponsors running head & neck squamous cell carcinoma studies include Gruppo Oncologico del Nord-Ovest, Rigshospitalet, Denmark, and Shandong Cancer Hospital and Institute.

Browse head & neck squamous cell carcinoma trials by phase

Treatments under study

About Head & Neck Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Head & Neck Squamous Cell Carcinoma? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head & Neck Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head & Neck Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.

Head & Neck Squamous Cell Carcinoma
University Hospital, Brest180 enrolled1 locationNCT07417605
Recruiting
Phase 3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting
Not Applicable

A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.

Head & Neck Squamous Cell Carcinoma
Rigshospitalet, Denmark40 enrolled1 locationNCT07506902
Recruiting
Phase 2

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

Head & Neck Squamous Cell Carcinoma
Gruppo Oncologico del Nord-Ovest45 enrolled1 locationNCT07485296
Recruiting

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
University of Rome Tor Vergata25 enrolled1 locationNCT07448727
Recruiting
Phase 3

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Head & Neck CancerHead & Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute335 enrolled1 locationNCT07333274